SB 2017-097: Prescription Drug Transparency Act (Passed)

[Associate Justice PiT]

You must be logged in to read this quote.

     Sponsor: SJoyce

     I hereby open the floor for debate.

[The world will shine with light in our nightmare]

I feel like this is information that would be known to the FDA if not the public already, considering the rigorous guidelines that drugmakers and pharmacists are held to with regard to record-keeping, among other things.  I would be interested to know if any event in particular encouraged the sponsor to introduce this bill.

[Donerail]

I feel like this is information that would be known to the FDA if not the public already, considering the rigorous guidelines that drugmakers and pharmacists are held to with regard to record-keeping, among other things.  I would be interested to know if any event in particular encouraged the sponsor to introduce this bill.

It generally isn't, no - there are no disclosure requirements that currently exist similar to those proposed in this legislation. The FDA certainly receives some testing data, but even they receive little financial information.

This legislation is inspired specifically by Mylan's EpiPen price increases, but there's been a broader trending of price increases across the pharmaceutical sector. If Mylan or any other company is increasing prices because they're spending more on R&D, then I think it'd be useful - for them and for us - for the public to know that. And if Mylan is spending more because they're spending more on marketing or executive compensation, I think that ought to be known too.

[The world will shine with light in our nightmare]

I feel like this is information that would be known to the FDA if not the public already, considering the rigorous guidelines that drugmakers and pharmacists are held to with regard to record-keeping, among other things.  I would be interested to know if any event in particular encouraged the sponsor to introduce this bill.

It generally isn't, no - there are no disclosure requirements that currently exist similar to those proposed in this legislation. The FDA certainly receives some testing data, but even they receive little financial information.

This legislation is inspired specifically by Mylan's EpiPen price increases, but there's been a broader trending of price increases across the pharmaceutical sector. If Mylan or any other company is increasing prices because they're spending more on R&D, then I think it'd be useful - for them and for us - for the public to know that. And if Mylan is spending more because they're spending more on marketing or executive compensation, I think that ought to be known too.

Makes sense.  This has got my support.

[Grumpier Than Thou]

Very necessary legislation. It has my support.

[Associate Justice PiT]

     Considering the substantial public largesse that these companies are receiving through various health care initiatives, I can agree that they owe the taxpayer a little transparency.

[Associate Justice PiT]

     There have been no comments on this in several days. If everyone is alright with this, I can bring it to a final vote in 24 hours.

[Associate Justice PiT]

     A final vote on this bill is now open. Please vote aye, nay, or abstain.

[The world will shine with light in our nightmare]

Aye.

[Donerail]

Aye

[Grumpier Than Thou]

Aye

[Associate Justice PiT]

     Aye. This bill has enough votes to pass. Senators have 24 hours to change their votes.

[Mike Thick]

AYE

[Anna Komnene]

Aye

[Associate Justice PiT]

You must be logged in to read this quote.

Atlasian Senate
Passed 6-0 in the Atlasian Senate assembled
Be it resolved, X Senator PiT, PPT[/quote]